medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2019, Number 4

<< Back Next >>

Rev Mex Patol Clin Med Lab 2019; 66 (4)

Hemostasis and factors associated with thrombotic tendency

Rodríguez DSC, Guzmán SS, Barreno RSG, Rubio JB, Nava ZAH

Language: Spanish
References: 29
Page: 227-233
PDF size: 265.21 Kb.


ABSTRACT

Hemostasis is the mechanism that maintains the balance between coagulation and fibrinolysis processes to physiologically repair vascular damage events. Primary hemostasis is generated by platelets through the phases of adhesion, aggregation and a phase of platelet content release and secondary hemostasis corresponds to the blood coagulation phase in which the coagulation factors participate and are activated. The activation of blood coagulation is given by an intrinsic and extrinsic pathway, and integratively studied its activation as the cellular model of coagulation that is constituted by the following stages, 1) initiation, 2) amplification, 3) propagation and, 4) clot stabilization. In this cellular model it is emphasized that the sequential activation of coagulation factors occurs on a cell surface where the fibrin network and the clot are formed. Thrombophilia is a clinical condition that conditions a thrombotic tendency which may be due to the presence of inherited factors or acquired factors, and one of the biomarkers of coagulation activation screening present in a thrombophilic state is D-dimer.


REFERENCES

  1. Thachil J, Lippi G, Favaloro EJ. D-dimer testing: laboratory aspects and current issues. Methods Mol Biol. 2017; 1646: 91-104.

  2. Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation. Blood Rev. 2015; 29 (1): 17-24.

  3. Rubio JB, Salazar PM, Nava A. Aspectos básicos sobre trombofilia, inflamación y autoinmunidad. Residente. 2012; 7 (1): 16-20.

  4. Dahlbäck B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med. 2005; 257 (3): 209-223.

  5. van der Meijden PEJ, Heemskerk JWM. Platelet biology and functions: new concepts and clinical perspectives. Nat Rev Cardiol. 2019; 16 (3): 166-179.

  6. Bauer KA. Selective inhibition of coagulation factors: advances in antithrombotic therapy. Semin Thromb Hemost. 2002; 28 Suppl 2: 15-24.

  7. Espitia-Huerter’O P. Actualidades en coagulación. Rev Mex Anest. 2015; 38 (S1): 143-146.

  8. Horan JT, Francis CW. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thromb Hemost. 2001; 27 (6): 657-666.

  9. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007; 27 (8): 1687-1693.

  10. Carrillo ER, Salmerón NP, Carvajal RR, Contreras DV, Hernández AC. Rompiendo un paradigma: del modelo humoral al modelo celular de la coagulación. Su aplicación clínica en el enfermo grave. Rev Asoc Mex Med Crit y Ter Int. 2004;18 (1): 17-23.

  11. Di Nisio M, Middeldorp S, Büller HR. Direct thrombin inhibitors. N Engl J Med. 2005; 353 (10): 1028-1040.

  12. Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D-dimer. J Am Coll Cardiol. 2017; 70 (19): 2411-2420.

  13. Rubio-Jurado B, Salazar-Páramo M, Medrano-Muñoz F, González-Ojeda A, Nava A. Trombofilia, autoinmunidad y tromboprofilaxis perioperatoria. Cir Cir. 2007; 75 (4): 313-321.

  14. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet. 2005; 365 (9465): 1163-1174.

  15. Virchow R. Esammelte Abhandlungen zur Wissenschaftlichen Medicin Frankfurt. edition SCR, editor. 1856.

  16. Martínez-Murillo C. Hacia un consenso nacional en tromboembolismo venoso. Gac Méd Méx. 2000; 136 (S2): S133-137.

  17. Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb Haemost. 2017; 117 (2): 219-230.

  18. Moll S. Thrombophilia: clinical-practical aspects. J Thromb Thrombolysis. 2015; 39 (3): 367-378.

  19. Reyes Utiérrez-Tous M. Trombofilia, ¿cuándo, qué pruebas y a quién? Seminarios de la Fundación Española de Reumatología. 2005; 6 (4): 133-143.

  20. Tofler GH, Massaro J, Levy D, Mittleman M, Sutherland P, Lipinska I et al. Relation of the prothrombotic state to increasing age (from the Framingham Offspring Study). Am J Cardiol. 2005; 96 (9): 1280-1283.

  21. Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013; 122 (12): 2011-2018.

  22. Halaby R, Popma CJ, Cohen A, Chi G, Zacarkim MR, Romero G et al. D-Dimer elevation and adverse outcomes. J Thromb Thrombolysis. 2015; 39 (1): 55-59.

  23. Chalmers JD, Singanayagam A, Scally C, Hill AT. Admission D-dimer can identify low-risk patients with community-acquired pneumonia. Ann Emerg Med. 2009; 53 (5): 633-638.

  24. Hargett CW, Tapson VF. Clinical probability and D-dimer testing: how should we use them in clinical practice? Semin Respir Crit Care Med. 2008; 29 (1): 15-24.

  25. Mountain D, Jacobs I, Haig A. The VIDAS D-dimer test for venous thromboembolism: a prospective surveillance study shows maintenance of sensitivity and specificity when used in normal clinical practice. Am J Emerg Med. 2007; 25 (4): 464-471.

  26. Ho CH. Can very high level of D-dimer exclusively predict the presence of thromboembolic diseases? J Chin Med Assoc. 2011; 74 (4): 151-154.

  27. Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood. 2009; 113 (13): 2878-2887.

  28. Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003; 349 (13): 1227-1235.

  29. Verhovsek M, Douketis JD, Yi Q, Shrivastava S, Tait RC, Baglin T et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med. 2008; 149 (7): 481-90, W94.




2020     |     www.medigraphic.com